3 The problem of obesity or overweight accounts for two-thirds of the U.S
Indeed, GLP-1RAs have evolved over time such that the frequency of dosing has decreased from twice-daily (exenatide, BD) [65], to once-daily (liraglutide, lixisenatide) [66, 67] to once-weekly (dulaglutide, exenatide QW, semaglutide) [5, 6], suggesting a higher adherence potential for the longer-acting agents (Table 2)
Measurable weight loss typically appears after 8 to 12 weeks of consistent treatment at therapeutic doses, with full results building over several months
Bioavailability is much better than an oral capsule that you swallow, but it can be variable, ranging between 1530% in small pilot studies